granocyte 13 million iu/ml, powder and solvent for injection/infusion in pre-filled syringe
central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - powder and solvent for solution for infusion or injection - lenograstim 13.4 million iu - immunostimulants
granocyte withdrawn form
chugai sanofi-aventis - lenograstim - withdrawn form
granocyte vial vial
sanofi aventis - lenograstim,human albumin,mannitol,polysorbate,sod.dihydrogen phos. - vial - 33.6miu.,1mg,50mg,0.1mg,6.5(ph) - vial
cranocyte 34
aventis pharma (pty) limited - combination - injection - lenograstim 33,6 miu (263 micrograms) - a recombinant glycoprotein equiv. to the human granulocyte colony stimulating factor (rh
lonquex
teva b.v. - lipegfilgrastim - neutropenia - immunostimulants, , colony stimulating factors - lonquex is indicated in adults and in children 2 years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
lonquex
abic marketing ltd, israel - lipegfilgrastim - solution for injection - lipegfilgrastim 6 mg / 0.6 ml - lipegfilgrastim - reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
lonquex solution for injection in pre-filled syringe 6mg0.6ml
teva pharmaceutical investments singapore pte. ltd. - lipegfilgrastim - injection, solution - lipegfilgrastim 6.00 mg/0.6ml
lonquex 6mg0.6ml solution for injection pre-filled syringes
teva uk ltd - lipegfilgrastim - solution for injection - 10mg/1ml
lonquex lipegfilgrastim (rbe) 6 mg/0.6 ml solution for injection prefilled syringe
teva pharma australia pty ltd - lipegfilgrastim, quantity: 6 mg - injection, solution - excipient ingredients: acetic acid; polysorbate 20; sorbitol; sodium hydroxide; water for injections - lonquex? is indicated for reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes)
granocyte 13 millionen ie/ml